Wall Street’s artificial intelligence trade is suddenly losing some of its grip on the market.
The S&P 500 finished higher Oct. 15 even as semiconductor stocks extended their sell-off, with investors rotating into more defensive parts of the market. Healthcare led eight of the index’s 11 sectors higher, while Eli Lilly (LLY) and UnitedHealth Group (UNH) were among the day’s strongest large-cap names, Reuters reported.
This trend is significant, since for most of the last two years, the market has rewarded businesses that invest in artificial intelligence.
Investors are now being forced to reevaluate where they want their money due to rising borrowing rates and concerns about whether large data-center investments will provide sufficient returns.
I find it noteworthy that the trend is more than just cash-hiding investors.
In the stock market, money is flowing from one area to another. That difference is important for anybody with an S&P 500 fund in their retirement account.
Even if the largest technology winners quit doing all the work, a shift toward healthcare might help sustain the sector as a whole.
Healthcare gets its moment as AI stocks stumble
When the economic environment becomes less predictable, investors tend to value a number of characteristics in the healthcare industry.
Even as consumer confidence declines, borrowing prices increase, or technology expenditure slows, people still need insurance, medication, and medical care.
Healthcare equities are nonetheless susceptible to market downturns. It does lessen their profits’ reliance on the same factors that investors are now concerned about in relation to artificial intelligence.
The contrast became particularly visible on Oct. 15. The Philadelphia Semiconductor Index declined for a seventh consecutive session, while Nvidia, Dell Technologies, and Hewlett Packard Enterprise were among the technology stocks under pressure.
Related: Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study
At the same time, healthcare led the S&P 500 higher, according to Reuters. Healthcare had not been the market’s leading industry, so the change is noteworthy.
The S&P 500 Health Care sector was up 6.74% for the year through Sept. 10. That lagged the broader market’s technology-driven advance.
Investors now have the opportunity to reevaluate the industry if they determine that the disparity between technology values and the rest of the market has become too great.
There are already indications of this trend. The Health Care Select Sector SPDR ETF (XLV), which tracks large U.S. healthcare companies, reached a record high this week as investors moved toward pharmaceutical and managed-care stocks, MarketWatch reported.
The fund offers investors an easy method to become involved in the industry without having to choose a specific pharmaceutical company or insurance provider, and it contains some of the biggest healthcare businesses in the S&P 500.
Because of this, the rotation is crucial, even for non-professional traders.
A wide index fund investor already owns these businesses. Even if they never make a deal, the makeup of their returns changes if healthcare begins to hold a larger share of the market as technology cools.
Eli Lilly and UnitedHealth show why investors are looking again
There are company-specific reasons why the healthcare rotation is taking place.
Due to the demand for its diabetes and obesity medications, Eli Lilly has emerged as one of the industry’s top growth stories, while UnitedHealth has been undergoing a multiyear operational turnaround.
Deutsche Bank upgraded both companies as part of a series of calls that helped lift healthcare shares Oct. 15, according to Reuters.
Additionally, UnitedHealth gave investors new proof that its recovery is moving forward. The company raised its 2026 adjusted earnings outlook to at least $20.50 a share after third-quarter results came in ahead of expectations. Adjusted earnings were $4.69 a share, while revenue reached $112.69 billion.
This approach provides investors with the visible profits that technology companies are increasingly fighting for.
The distinction does not imply that artificial intelligence will no longer be a major long-term trend in the market or that healthcare will suddenly become risk-free.
More Healthcare:
- Health insurance is about to cost you a lot more in 2027
- Medicare shoppers face a hidden AI problem this open enrollment
- Pepsi, Nestle could save 150,000 lives a year with one simple change
Investors now have another option.
Sitting outside of mega-cap technology over a large portion of the AI rise meant taking the risk of being significantly behind the index.
If healthcare businesses are increasing their profits while investors are wondering what they are ready to pay for future AI gains, then that equation changes.
If interest rates continue to rise, the change may become very significant.
In order to construct data centers and buy processors, many of the businesses at the heart of the AI infrastructure development rely on massive sums of money. That expansion is more costly due to higher borrowing costs.
The business models of a huge pharmaceutical firm that sells medications and an insurance company that collects premiums are significantly different.
For this reason, it’s worth keeping an eye on this week’s rotation.
Investors now need to see whether the rotation lasts
One or two powerful sessions do not create a new market regime.
During times of volatility, money often briefly shifts into defensive equities before returning to technology as soon as the anxiety subsides.
The contrast should become more apparent in the coming weeks. Investors may be looking at something more important than a short-term safe-haven move if healthcare continues to outperform even after technology recovers.
For the S&P 500 as a whole, it would be significant. For market gains and earnings growth, the index has grown abnormally reliant on a limited number of mega-cap firms. A real rotation into consumer staples, healthcare, finance, and other fields would distribute the load across more businesses.
In fact, it could be a better result for the typical investor. A market that grows because hundreds of businesses are doing well is less reliant on a flawless quarter from Nvidia or another tech behemoth.
There are still many factors that might encourage investors to return to AI. Strong mega-cap profits, reduced lending rates, or proof that data-center investment is yielding higher returns might swiftly rekindle enthusiasm.
However, Wall Street is shown a readiness to go elsewhere — something it hasn’t needed to do much throughout the artificial intelligence boom.
Healthcare is now receiving its first serious examination.
The issue of whether the AI boom is complete is no longer relevant to investors. Instead, it’s whether AI needs to lead at all in the next phase of the bull market.
Related: Eli Lilly CEO delivers stark message on what comes next
